Types of Lymphoma and Leukemia
Lymphomas: Hodgkin (HL), DLBCL, follicular, mantle cell, Burkitt. Leukemias: AML, ALL, CLL, CML. Each has distinct biology, staging and treatment.
Hodgkin Lymphoma: Curable
ABVD chemotherapy: 85-92% 5-year survival. Advanced disease: escalated BEACOPP or brentuximab vedotin combinations. Checkpoint inhibitors for r/r HL.
🆕 Bispecific Antibodies 2024
Glofitamab (CD20×CD3) and Mosunetuzumab are FDA-approved for r/r DLBCL and follicular lymphoma. Outpatient, 30-60 minutes. Alongside CAR-T as major 2024 advances.
AML: Venetoclax Revolution
Venetoclax (BCL-2 inhibitor) + Azacitidine is now standard for elderly/unfit AML patients. IDH1/2 mutations: Ivosidenib, Enasidenib targeted therapy. FLT3+: Midostaurin or Quizartinib.
💰 Cost
Chemotherapy (RCHOP 6 cycles): $8,000-20,000 Istanbul (USA: $50,000-150,000). 60-80% savings.